ArticleJournal of orthopaedic research : official publication of the Orthopaedic Research Society2026
A Biomechanical Proof-of-Concept Study of Scaffold-Augmented Distraction Osteogenesis Using 3D-Printed Hyperelastic Bone™ in a Rabbit Tibial Lengthening Model.
Article in Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Distraction osteogenesis (DO) for limb lengthening often requires prolonged fixation while the regenerate consolidates. Adjuncts that improve the regenerate quality could reduce morbidity and treatment time. Hyperelastic Bone™ (HEB) is a 3D-printed hydroxyapatite (HA)/polylactic-co-glycolic acid (PLGA) scaffold, but its efficacy as an osteotomy-site adjunct during DO is unclear. After IACUC approval, rabbits underwent left tibial lengthening with a mini-rail external fixator distracted at 0.75 mm/day to 20% tibial length and received no scaffold (control), traditional Hyperelastic Bone™ (10% PLGA/90% HA), or a biphasic formulation (10% PLGA/70% HA/20% β-tricalcium phosphate [β-TCP]) placed subperiosteally at the osteotomy site. The contralateral tibiae served as references. After 8 weeks of consolidation, radiographs, micro-CT (prespecified endpoint: regenerate BMD), and torsional testing (prespecified endpoint: stiffness) were performed. Fourteen rabbits underwent attempted lengthening. Intraoperative fractures (n = 2) and fixation loss (n = 3) reduced complete terminal datasets to nine, all of which completed micro-CT and torsion testing. Radiographs confirmed regenerate formation. Regenerate BMD remained below contralateral values with controls being intermediate to the traditional and biphasic HEB formulations (60.5%, 63.8%, and 54.7% of contralateral, respectively). Despite no mineral density improvement, scaffold-treated regenerate demonstrated higher torsional stiffness and strength metrics, greatest with the biphasic formulation, with lower failure displacement and higher polar moment of inertia. Statement of Clinical Significance: A scaffold that improves functional regenerate performance could enable earlier safer weight bearing and device removal and reduce nonunion/refracture risk in DO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.